drugset / Trial / NCT01187888
Efficacy, Tolerability and Safety of Azilect in Subjects With Progressive Supranuclear Palsy
Phase 3
Terminated
44 enrolled
Prof. Dr. Stefan Lorenzl
Ludwig-Maximilians - University of Munich · collabTeva Branded Pharmaceutical Products R&D, Inc. · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine whether rasagiline is effective in the treatment of Progressive Supranuclear Palsy (PSP), a rapidly progressing disease with a symptomatology similar to Parkinson's Disease. The major aim of this study is the limitation or halting of the process of neurodegeneration and influence postural instability.
Timeline
- Start
- 2010-01
- Primary completion
- 2012-06
- Completion
- 2012-06
Outcome
Outcome not reported
Stopped: “IMP used off label by phys. in pat. with PSP. Thus no more eligible patients were available for the study(pre-treatm.with Rasagiline=exclusion criterion”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Rasagiline | Small molecule | 1 mg | — |